Kala Pharmaceuticals ( (KALA) ) has released its Q3 earnings. Here is a breakdown of the information Kala Pharmaceuticals presented to its investors.
Kala Pharmaceuticals, operating under the name KALA BIO, is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe eye diseases, leveraging its proprietary mesenchymal stem cell secretome (MSC-S) platform.
In its latest earnings report, KALA BIO announced ongoing patient enrollment in its Phase 2b CHASE trial for KPI-012, a potential first-in-class treatment for Persistent Corneal Epithelial Defect (PCED). The company initiated clinical trial sites in Argentina and plans for additional locations in Latin America, with topline results anticipated in the second quarter of 2025.
Key financial highlights include a decrease in cash reserves to $49.2 million as of September 30, 2024, along with reduced general and administrative expenses, which were $4.4 million for the quarter. Research and development expenses slightly decreased to $5.2 million. The net loss for the quarter was $9.0 million, with an operating loss of $10.0 million. However, the company remains financially poised to fund operations into the fourth quarter of 2025.
KALA BIO’s strategic focus extends beyond PCED, exploring the potential of KPI-012 for additional eye diseases like Limbal Stem Cell Deficiency and its MSC-S platform for retinal degenerative diseases, suggesting a broad and impactful product pipeline.
Looking ahead, KALA BIO anticipates significant milestones in its clinical programs, with the potential to advance treatment options for ocular diseases through continued research and strategic development of its MSC-S platform.
